Demographic and clinical data. Values are mean (range) unless otherwise specified.
| Variable | Treatment Change, n = 161 | No Treatment Change, n = 342 | Combined, n = 503 |
|---|---|---|---|
| Age, yrs | 50.0 (20–84) | 51.2 (19–87) | 50.8 (19–87) |
| Male/female, n | 89/72 | 197/145 | 286/217 |
| PsA duration, yrs | 8.9 (0.1–51) | 10.2 (0.1–54) | 9.8 (0.1–54) |
| Psoriasis duration, yrs | 17.5 (0.1–55) | 18.7 (0.3–68) | 18.4 (0.1–68) |
| TJC | 10.2 (0–57) | 5.9 (0–66) | 7.2 (0–66) |
| SJC | 4.4 (0–50) | 2.9 (0–62) | 3.4 (0–62) |
| PASI | 5.1 (0–45) | 3.8 (0–58) | 4.2 (0–58) |
| HAQ | 1.03 (0–2.88) | 0.59 (0–2.88) | 0.73 (0–2.88) |
| PASDAS | 5.3 (1.5–8.3) | 3.8 (0.4–9.0) | 4.3 (0.4–9.0) |
| CPDAI | 6.8 (1–13) | 4.8 (1–13) | 5.4 (1–13) |
| MDA, n (%) | 12 (7.5) | 103 (30) | 115 (23) |
PsA: psoriatic arthritis; TJC: tender joint count; SJC: swollen joint count; PASI: Psoriasis Area and Severity Index; CPDAI: Composite Psoriatic Disease Activity Index; PASDAS: Psoriatic Arthritis Disease Activity Score; HAQ: Health Assessment Questionnaire; MDA: minimal disease activity.